novartis semaglutide glp 1 drug Novo's Wegovy becomes first GLP-1 drug approved for MASH Semaglutide shortage ends as FDA

Skin Type Quick-Reference Table Pro Tip: Don't skip the patch test

Weight loss is most sustainable when it is steady rather than extremely rapid

Tracking symptoms and staying in contact with your doctor or pharmacist is the best way to manage side effects without stopping treatment prematurely

Inject 30 to 60 minutes before sexual activity

Its well established that obesity is linked to increased risk of several diseases, including: Cardiovascular disease Diabetes Certain types of cancer Dementia And the menopause transition further increases our risk of these diseases

So if you are still overeating, it does not mean the medication is not working